The first effective solution to a long-standing problem
For decades, roughly one in three breast cancer patients prescribed tamoxifen have received a treatment their own biology could not fully activate — a quiet, genetic inequity embedded in standard care. German researchers have now published evidence that directly supplementing tamoxifen with its active metabolite, (Z)-endoxifen, closes that gap for younger patients who lack the enzyme needed to make the conversion themselves. It is a small biochemical adjustment with large human consequences, and it points toward a medicine that listens more carefully to the individual body before it prescribes.
- A genetic variation in roughly one-third of breast cancer patients silently renders tamoxifen — one of the most common treatments in oncology — far less effective than it should be.
- Premenopausal women have borne this gap most acutely, as the alternative drug class available to older patients simply does not apply to them.
- A German trial of 235 patients demonstrated that combining tamoxifen with direct doses of (Z)-endoxifen restores therapeutic drug levels, with side effects no worse than standard treatment.
- The lead researcher described it as 'the first effective solution to a long-standing problem' — language that signals not incremental progress but a genuine closure of a decades-old treatment failure.
- A U.S. mid-stage trial is now testing the combination specifically in premenopausal women, with researchers also watching whether the approach might extend to unrelated tissue injuries.
About one in three patients taking tamoxifen for breast cancer carry a genetic variation that limits their body's ability to convert the drug into its active form. The culprit is a deficiency in an enzyme called CYP2D6, which is responsible for transforming tamoxifen into (Z)-endoxifen — the compound that actually blocks estrogen from feeding cancer cell growth. Without sufficient enzyme activity, the drug circulates largely inert. For postmenopausal women, aromatase inhibitors offer an alternative. For younger, premenopausal patients, no comparable substitute has existed.
German researchers at the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology in Stuttgart have now published results from a 235-patient study suggesting a direct remedy: simply give low-metabolizing patients both tamoxifen and (Z)-endoxifen together. Patients on the combination therapy reached the same active drug concentrations in their blood as patients with normal enzyme levels taking tamoxifen alone. Side effects were mild and comparable across both groups.
Dr. Matthias Schwab, who led the research, called it 'the first effective solution to a long-standing problem.' The approach fits within the broader movement toward precision medicine — using a straightforward genetic test to identify which patients need the combination, rather than applying a uniform dose and hoping for the best.
A mid-stage trial is already underway in the United States, focused on premenopausal women with newly diagnosed early-stage hormone-responsive breast cancer. Researchers are also exploring whether (Z)-endoxifen might have applications in treating other tissue injuries, though breast cancer remains the immediate and most pressing focus.
About one in three breast cancer patients who take tamoxifen—one of the most widely prescribed treatments for the disease—don't get the full benefit they need. The reason is genetic: their bodies don't produce enough of an enzyme called CYP2D6, which is essential for converting tamoxifen into its active form, a compound called (Z)-endoxifen. Without that conversion, the drug sits in their bloodstream largely inert, unable to do its job of blocking estrogen from fueling cancer cell growth. For postmenopausal women, doctors have alternatives—a class of drugs called aromatase inhibitors. For younger, premenopausal patients, there have been no good options. Until now, perhaps.
German researchers have published results suggesting a straightforward solution: give patients who can't metabolize tamoxifen properly a combination of tamoxifen plus (Z)-endoxifen directly. The study involved 235 patients with early-stage hormone-dependent breast cancer. Some received tamoxifen alone; others received the combination therapy, selected based on whether their bodies were converting the drug effectively. The outcome was clean: patients on combination therapy achieved the same blood concentrations of the active drug as patients with normal enzyme levels who took tamoxifen alone. Side effects were mild in both groups and comparable to each other.
Dr. Matthias Schwab, who led the research at the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology in Stuttgart, called the finding "the first effective solution to a long-standing problem." That language matters. This isn't a marginal improvement or a theoretical possibility. This is a treatment gap that has existed for decades, affecting roughly a third of all tamoxifen patients, finally being addressed with a method that works.
The approach represents a shift toward what's sometimes called precision medicine—tailoring treatment not to a diagnosis alone but to the individual biology of the patient receiving it. In this case, a simple genetic test could identify which patients have low CYP2D6 levels, and those patients could immediately be offered the combination approach rather than hoping a standard dose of tamoxifen will work for them.
The research is already moving forward. A mid-stage trial is underway in the United States testing (Z)-endoxifen specifically in premenopausal women with newly diagnosed early-stage hormone-responsive breast cancer. If those results hold, the therapy could become standard practice for a subset of patients who have had few good choices. The study also hints at broader applications—researchers are exploring whether the same approach might work for other conditions, including blood vessel injuries and abdominal wall damage. But for now, the focus remains on breast cancer, where the need is clear and the solution, at last, appears to be at hand.
Notable Quotes
We are offering the first effective solution to a long-standing problem: the insufficient effect of tamoxifen in a significant proportion of patients.— Dr. Matthias Schwab, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
The Hearth Conversation Another angle on the story
Why does this matter so much if it's just one drug combined with another?
Because for thirty years, a third of patients taking tamoxifen weren't actually getting treated. Their bodies couldn't activate the drug. They had no alternative. This closes that gap.
So it's not that tamoxifen is broken—it's that some people's bodies can't use it?
Exactly. The drug works fine. The problem is the enzyme that activates it. Some people inherit low levels of CYP2D6. It's not a flaw in them; it's just how their genetics work.
And you can test for this before giving someone tamoxifen?
Yes. A genetic test can identify who has low enzyme levels. Then instead of gambling on whether tamoxifen alone will work, you know upfront and can offer the combination.
What's the catch? Why hasn't this been done before?
The active form, (Z)-endoxifen, had to be synthesized and studied. It's not something that was easy to produce or test until recently. Now that it is, the path forward is clear.
Are there side effects from adding the second compound?
No more than from tamoxifen alone. That's what surprised no one and reassured everyone. It works and it's safe.
What happens next?
The U.S. trial will tell us if this works in premenopausal women specifically. If it does, it becomes standard care for patients with low enzyme levels. The real question is how quickly doctors adopt genetic testing to identify who needs it.